Pacer BioThreat Strategy ETF (VIRS)
| Assets | $5.58M |
| NAV | $27.91 |
| Expense Ratio | 0.70% |
| PE Ratio | 26.90 |
| Shares Out | 200,000 |
| Dividend (ttm) | $0.14 |
| Dividend Yield | 0.49% |
| Ex-Dividend Date | Mar 24, 2022 |
| 1-Year Return | -7.52% |
| Volume | 150 |
| Open | 31.04 |
| Previous Close | 27.54 |
| Day's Range | 27.54 - 28.11 |
| 52-Week Low | 28.30 |
| 52-Week High | 35.32 |
| Beta | 0.80 |
| Holdings | 51 |
| Inception Date | Jun 24, 2020 |
About VIRS
The index is generally composed of U.S.-listed stocks of companies whose products or services help protect against, endure, or recover from biological threats to human health. The Advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. It is non-diversified.
Top 10 Holdings
52.96% of assets| Name | Symbol | Weight |
|---|---|---|
| Merck & Co. | MRK | 7.78% |
| Johnson & Johnson | JNJ | 6.52% |
| Walmart | WMT | 5.23% |
| Thermo Fisher Scientific | TMO | 5.21% |
| Sanofi | SNY | 5.17% |
| Abbott Laboratories | ABT | 5.15% |
| Danaher | DHR | 4.80% |
| CVS Health | CVS | 4.70% |
| Lowe's Companies | LOW | 4.29% |
| The Home Depot | HD | 4.13% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2021 | $0.04255 | Sep 29, 2021 |
| Jun 21, 2021 | $0.0948 | Jun 25, 2021 |
| Mar 22, 2021 | $0.05936 | Mar 26, 2021 |
| Dec 21, 2020 | $0.03944 | Dec 28, 2020 |
| Sep 21, 2020 | $0.04845 | Sep 25, 2020 |
News
Biothreat ETF (VIRS) Hits New 52-Week High
The Biothreat ETF hit a new 52-week high. Can it soar further?
Bet On COVID-Themed ETFs as New Cases Rise Globally
The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.
Play COVID-Themed ETFs as US Labor Day Sees Rise in New Cases
The remainder of 2021 is expected to continue reeling under the spurt in coronavirus cases. Thus, a COVID-themed ETF could be a wise choice.
Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
5 Sector ETFs At All-Time Highs
We have highlighted five ETFs from different sectors that hit new peaks in the recent trading session and have been the leaders in their respective sector so far this year.
COVID Biotech ETFs Rise At Fever Pace
ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.
Are COVID-Themed ETFs Back in Focus as Delta Variant Fears Rise?
The rest of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
ETFs to Watch Ahead of Netflix Q2 Earnings
After disappointing first-quarter earnings results, with lesser subscriber growth, investors are keen to watch whether Netflix managed to win subscribers in the second quarter amid stiff competition.
What's in Store for COVID-Themed ETFs as New Cases Rise?
The first half of 2021 is expected to continue bearing the brunt of the coronavirus outbreak considering the pandemic's renewed resurgence thanks to variants. Thus, a COVID-themed ETF could be a smart p...
COVID-Themed ETFs in Focus Amid Soaring Cases
The first half of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
COVID-Themed ETFs in Focus as Cases Soar Post Thanksgiving
The rest of 2020 and the beginning of 2021 are expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
These are the ETFs with the most exposure to the year's best-performing stock
Semiconductor behemoth Nvidia Corp. is the biggest gainer in the S&P 500 for the year to date, up 127%, heftily ahead of second-place West Pharmaceuticals Inc. , which has only gained 87%. The exchange-...
Coronavirus-Themed ETFs in Focus as the Pandemic Worsens
The remainder of 2020 is expected to continue bearing the brunt of the coronavirus outbreak and therefore, a COVID-19-themed ETF could be a smart pick.
ETFs to Win From the Netflix, Amazon Q3 Earnings Faceoff
Both companies have reasonable chances of beating earnings estimates with Netflix witnessing positive earnings estimate revisions. On the other hand, Amazon saw negative earnings estimate revision.
5 Coronavirus-Themed ETFs That Can Fight the Pandemic Scares
It feels like the rest of 2020 will continue to bear the brunt of the coronavirus outbreak and therefore, a COVID-19-themed ETF could be a smart pick.
Nvidia's Buyout of Designer Arm Put These ETFs in Focus
The news has put the spotlight on some ETFs, which could be the best ways for investors to tap the opportunity arising from the proposed Nvidia deal.
3 ETFs For Nvidia's Big Arm Holdings Acquisition
News broke Saturday that semiconductor giant Nvidia (NASDAQ: NVDA) is in talks to acquire Arm Holdings, a UK-based chip designer, from Japan's SoftBank Group for $40 billion.
Should You Invest in Coronavirus ETFs?
There are advantages -- and disadvantages -- to some of the newest ETFs on the market.
Direxion Debuts CCON ETF, Expands COVID-19-Themed Product Base
In the current scenario of the rising work-from-home and online shopping trends, online learning, home entertainment, telemedicine and digital health services are slowly becoming the "new normal."
An Outperforming ETF for a Post-Coronavirus Pandemic World
The Pacer BioThreat Strategy ETF (VIRS) is an outperforming healthcare sector-related exchange traded fund that has benefited from exposure to areas outside of the healthcare solutions category. Over th...
Direxion Debuts CCOC ETF, Expands COVID-19-Themed Product Base
In the current scenario of the rising work-from-home and online shopping trends, online learning, home entertainment, telemedicine and digital health services are slowly becoming the "new normal."
Should You Invest in COVID Themed ETFs?
We highlight three new ETFs that seek to capitalize on coronavirus.
ETFs to Watch as Netflix Drops on Weak Subscriber Outlook
While Netflix beat revenue estimates and reported solid subscriber addition, it missed the earnings estimate and offered weak third-quarter subscriber guidance.
ETFs to Buy as Netflix Tops Disney Ahead of Q2 Earnings
The outperformance for Netflix is expected to continue given that the company has strong chances of beating estimates for the second quarter and witnessed positive earnings estimate revisions.
